All In Biotech

Drug Trial Radar · NCT03750383

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Feb 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Nov 2, 2018

Primary completion

Nov 17, 2018

Study completion Dec 13, 2018

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
Pharmaceutical Research Associates
First posted
Nov 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects

Conditions

  • RSV Infection

Interventions

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)

  • EDP-938Drug

    Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)

  • CyclosporineDrug

    Subjects will receive one dose of cyclosporine on Day 5

  • PrednisoneDrug

    Subjects will receive prednisone once daily from Day 5 to Day 14

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of EDP-938 with and without coadministration with cyclosporineTime frame: Up to 12 days
  2. AUC of EDP-938 with and without coadministration with cyclosporineTime frame: Up to 12 days
  3. Cmax of EDP-938 with and without coadministration with prednisoneTime frame: Up to 21 days
  4. AUC of EDP-938 with and without coadministration with prednisoneTime frame: Up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaceutical Research Associates, Inc.,

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.